Brawn Biotech

{
  "main_header": {
    "sid": 479596,
    "name": "Brawn Biotech",
    "stock_name": "Brawn Biotech",
    "full_name": "Brawn Biotech Ltd",
    "name_url": "stocks-analysis/brawn-biotech",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 0,
    "country_id": 34,
    "currency": "INR",
    "cmp": "20.05",
    "chg": "0.00",
    "chgp": "0.00%",
    "dir": 0,
    "prev_price": "20.05",
    "mcapval": "6.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 530207,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 49,
    "sector_id": 65,
    "indexname": "India SENSEX",
    "isin": "INE899B01015",
    "curr_date": "Jun 10, 03:30 PM",
    "curr_time": "08:46 AM",
    "last_traded_at": "Jun 10, 03:30 PM IST",
    "bse_nse_vol": "860 ",
    "exc_status": "Active",
    "traded_date": "Jun 10, 2026",
    "traded_date_str": "2026 06 10",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/brawn-biotech-479596-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Are Brawn Biotech Ltd latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-brawn-biotech-ltd-latest-results-good-or-bad-4021761",
        "imagepath": "",
        "date": "2026-05-29 19:36:43",
        "description": "Brawn Biotech Ltd's latest financial results reflect a challenging operational environment. In Q2 FY26, the company reported a net loss of ₹0.04 crores, a significant shift from a profit of ₹0.23 crores in the previous quarter. This change was largely attributed to a lack of other income, which had previously contributed positively to profitability. Revenue remained flat at ₹0.12 crores, indicating stagnation in sales performance.\n\nThe operating margin, excluding other income, fell sharply to -33.33%, contrasting with a positive margin of 25.0% in Q1 FY26. This substantial decline highlights significant operational inefficiencies and cost pressures that the company has been unable to manage effectively. Additionally, the return on equity for the latest fiscal year stood at -16.49%, indicating a failure to generate positive returns for shareholders.\n\nOver the past five years, Brawn Biotech has experienced a ..."
      },
      {
        "title": "When is the next results date for Brawn Biotech Ltd?",
        "link": "https://www.marketsmojo.com/news/result-analysis/when-is-the-next-results-date-for-brawn-biotech-ltd-4007250",
        "imagepath": "",
        "date": "2026-05-22 23:18:06",
        "description": "The next results date for Brawn Biotech Ltd is scheduled for 29 May 2026...."
      },
      {
        "title": "Brawn Biotech Ltd Upgraded to Sell on Technical Improvements Despite Lingering Fundamental Challenges",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/brawn-biotech-ltd-upgraded-to-sell-on-technical-improvements-despite-lingering-fundamental-challenges-3948302",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/BrawnBiotechLtd_mojoScore_3948302.png",
        "date": "2026-04-16 08:04:44",
        "description": "Brawn Biotech Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Strong Sell to Sell as of 15 Apr 2026. This change reflects a nuanced shift driven primarily by technical indicators improving to mildly bullish territory, even as fundamental and valuation concerns persist. The stock’s recent price performance and financial results provide a mixed picture that investors should carefully analyse."
      },
      {
        "title": "Brawn Biotech Ltd Downgraded to Strong Sell Amid Technical and Fundamental Weaknesses",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/brawn-biotech-ltd-downgraded-to-strong-sell-amid-technical-and-fundamental-weaknesses-3931226",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/BrawnBiotechLtd_mojoScore_3931226.png",
        "date": "2026-04-03 08:01:41",
        "description": "Brawn Biotech Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has been downgraded from a Sell to a Strong Sell rating as of 2 April 2026. This revision reflects a deterioration across multiple key parameters including technical indicators, valuation metrics, financial trends, and overall quality assessment. The downgrade comes amid a sharp decline in share price and persistent operational challenges, signalling heightened risk for investors."
      },
      {
        "title": "Brawn Biotech Ltd Downgraded to Strong Sell Amid Technical and Fundamental Concerns",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/brawn-biotech-ltd-downgraded-to-strong-sell-amid-technical-and-fundamental-concerns-3895734",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/BrawnBiotechLtd_mojoScore_3895734.png",
        "date": "2026-03-17 08:03:20",
        "description": "Brawn Biotech Ltd has seen its investment rating downgraded from Sell to Strong Sell as of 16 Mar 2026, reflecting a deterioration in its technical outlook and persistent fundamental challenges. Despite some positive quarterly financial results, the company’s long-term growth trajectory and valuation metrics remain concerning, prompting a reassessment of its investment appeal within the Pharmaceuticals & Biotechnology sector."
      }
    ],
    "total": 421,
    "sid": "479596",
    "stock_news_url": "https://www.marketsmojo.com/news/brawn-biotech-479596"
  },
  "announcements": [
    {
      "caption": "Intimation Regarding Non-Applicability Of Regulation 23(9)",
      "datetime": "30-May-2026",
      "details": "Intimation regarding non-applicability of Regulation 23(9)",
      "source": "BSE"
    },
    {
      "caption": "Compliances-Reg.24(A)-Annual Secretarial Compliance",
      "datetime": "30-May-2026",
      "details": "BSE Intimation for Non-Applicability of Annual Secretarial Compliance Report under Regulation 24A",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "30-May-2026",
      "details": "Newspaper publication of Audited Financial Results for Quarter and Year ended 31.03.2026",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Brawn Biotech Ltd has declared <strong>10%</strong> dividend, ex-date: 12 Sep 18",
          "dt": "2018-09-12",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Are Brawn Biotech Ltd latest results good or bad?

2026-05-29 19:36:43

Brawn Biotech Ltd's latest financial results reflect a challenging operational environment. In Q2 FY26, the company reported a net loss of ₹0.04 crores, a significant shift from a profit of ₹0.23 crores in the previous quarter. This change was largely attributed to a lack of other income, which had previously contributed positively to profitability. Revenue remained flat at ₹0.12 crores, indicating stagnation in sales performance. The operating margin, excluding other income, fell sharply to -33.33%, contrasting with a positive margin of 25.0% in Q1 FY26. This substantial decline highlights significant operational inefficiencies and cost pressures that the company has been unable to manage effectively. Additionally, the return on equity for the latest fiscal year stood at -16.49%, indicating a failure to generate positive returns for shareholders. Over the past five years, Brawn Biotech has experienced a ...

Read full news article

When is the next results date for Brawn Biotech Ltd?

2026-05-22 23:18:06

The next results date for Brawn Biotech Ltd is scheduled for 29 May 2026....

Read full news article

Brawn Biotech Ltd Upgraded to Sell on Technical Improvements Despite Lingering Fundamental Challenges

2026-04-16 08:04:44

Brawn Biotech Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Strong Sell to Sell as of 15 Apr 2026. This change reflects a nuanced shift driven primarily by technical indicators improving to mildly bullish territory, even as fundamental and valuation concerns persist. The stock’s recent price performance and financial results provide a mixed picture that investors should carefully analyse.

Read full news article

Brawn Biotech Ltd Downgraded to Strong Sell Amid Technical and Fundamental Weaknesses

2026-04-03 08:01:41

Brawn Biotech Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has been downgraded from a Sell to a Strong Sell rating as of 2 April 2026. This revision reflects a deterioration across multiple key parameters including technical indicators, valuation metrics, financial trends, and overall quality assessment. The downgrade comes amid a sharp decline in share price and persistent operational challenges, signalling heightened risk for investors.

Read full news article

Brawn Biotech Ltd Downgraded to Strong Sell Amid Technical and Fundamental Concerns

2026-03-17 08:03:20

Brawn Biotech Ltd has seen its investment rating downgraded from Sell to Strong Sell as of 16 Mar 2026, reflecting a deterioration in its technical outlook and persistent fundamental challenges. Despite some positive quarterly financial results, the company’s long-term growth trajectory and valuation metrics remain concerning, prompting a reassessment of its investment appeal within the Pharmaceuticals & Biotechnology sector.

Read full news article

View All News